Status: Finalised First registered on: 11/12/2014
Last updated on: 27/08/2020
1. Study identification
EU PAS Register NumberEUPAS8205
Official titleRisk of subsequent cardiovascular events in patients discharged after myocardial infarction - Perseus
Study title acronymPERSEUS
Study typeObservational study
Brief description of the studyMyocardial infarction affects about 5000 patients in Finland per year. Almost 20% of them die within one year after the event. Among the Nordic countries, cardiovascular death rates are the highest in Finland. Current guidelines advise to treat myocardial infarction patients with 12-month dual antiplatelet treatment. An ongoing PEGASUS-TIMI 54 clinical study aims to survey the advantages of longer use of ticagrelor and acetylsalicylic acid in secondary prevention. The aim of the present study is to describe the risk development and risk factors of subsequent cardiovascular events in patients discharged from hospital after myocardial infarction. The study questions focus on patients surviving more than one year without subsequent myocardial infarction or stroke and on patients with known additional risk factors. Pre-specified subgroup analyses in populations mimicking the PEGASUS-TIMI 54 study population in a real-life setting will be performed to enable comparison of real-life and randomised study settings.
Was this study requested by a regulator?No
Is the study required by a Risk Management Plan (RMP)? Not applicable
Regulatory procedure number (RMP Category 1 and 2 studies only)
Other study registration identification numbers and URLs as applicableAstra Zeneca: D1843R00244; EPID Research: ER-9502
2. Research centres and Investigator details
Coordinating study entity
Centre to which the investigator belongsEPID Research
Department/Research group
Organisation/affiliationEPID Research Oy
Website/Homepagewww.epidresearch.com
Details of (Primary) lead investigator
Title Dr
Last name Prami
First name Tuire
Is this study being carried out with the collaboration of a research network?
No
Other centres where this study is being conducted
Not applicable (single centre)

Countries in which this study is being conducted
National study

Finland
3. Study timelines: initial administrative steps, progress reports and final report
PlannedActual
Date when funding contract was signed04/11/2014
Start date of data collection01/09/201512/08/2015
Start date of data analysis01/09/201515/10/2015
Date of interim report, if expected
Date of final study report30/06/201617/05/2016
4. Sources of funding
Please provide estimates of the percentage of funding by source for this study
Names(s)Approximate % funding
Pharmaceutical companiesAstraZeneca Nordic Baltic100
Charities
Government body
Research councils
EU funding scheme
5. Contact details for enquiries
Scientific Enquiries
Title Dr
Last name Prami
First name Tuire
Address line 1EPID Research Oy
Address line 2Metsänneidonkuja 12 
Address line 3 
CityEspoo 
Postcode02130 
CountryFinland
Phone number (incl. country code)358-50-5468459 
Alternative phone number 
Fax number (incl. country code) 
Email address tuire.prami@epidresearch.com
Public Enquiries
Title Dr 
Last name Prami 
First name Tuire 
Address line 1EPID Research Oy 
Address line 2Metsänneidonkuja 12 
Address line 3 
CityEspoo 
Postcode02130 
CountryFinland 
Phone number (incl. country code)358-50-5468459 
Alternative phone number 
Fax number (incl. country code) 
Email address tuire.prami@epidresearch.com 
Top